Beta thalassemia-Pipeline Insight, 2021 | Analytical Research Cognizance

Beta thalassemia-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667933
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Beta thalassemia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Beta thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Beta thalassemia Understanding
Beta thalassemia: Overview
Beta thalassemia is an inherited blood disorder that reduces the production of hemoglobin. Affected individuals also have a shortage of red blood cells (anemia), which can cause pale skin, weakness, fatigue, and more serious complications. People with beta thalassemia are at an increased risk of developing abnormal blood clots. The characteristic finding of beta thalassemia is anemia, which is caused because red blood cells are abnormally small (microcytic), are not produced at the normal amounts, and do not contain enough functional hemoglobin. Beta thalassemia can be classified into two types depending on the severity of symptoms: thalassemia major (also known as Cooley's anemia) and thalassemia intermedia. Of the two types, thalassemia major is more severe. Blood tests for diagnosis of Beta thalassemia can reveal the number of red blood cells and abnormalities in size, shape or color. Blood tests can also be used for DNA analysis to look for mutated genes. Mild forms of thalassemia trait don't need treatment. For moderate to severe thalassemia, treatments might include: frequent blood transfusions, chelation therapy, and stem cell transplant.

"Beta thalassemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta thalassemia pipeline landscape is provided which includes the disease overview and Beta thalassemia treatment guidelines. The assessment part of the report embraces, in depth Beta thalassemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Beta thalassemia R&D. The therapies under development are focused on novel approaches to treat/improve Beta thalassemia.

Beta thalassemia Emerging Drugs Chapters
This segment of the Beta thalassemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Beta thalassemia Emerging Drugs
CTX001: CRISPR Therapeutics
CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from β-thalassemia and sickle cell disease. The drug is in Phase I/II clinical evaluation for the treatment of β-thalassemia. CTX001 has been designated an orphan drug in the U.S. and Europe, and given fast track, rare pediatric disease, and regenerative medicine advanced therapy designations in the U.S. for SCD and transfusion-dependent beta thalassemia (TDT).

IMR-687: Imara
IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD) and β-thalassemia. IMR-687 is a highly selective, potent small molecule inhibitor of PDE9 (Phosphodiesterase 9A). Imara has evaluating the drug in Phase 2b clinical trial for patients with beta-thalassemia. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassaemia.
Further product details are provided in the report……..

Beta thalassemia: Therapeutic Assessment
This segment of the report provides insights about the different Beta thalassemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Beta thalassemia
There are approx. 22+ key companies which are developing the therapies for Beta thalassemia. The companies which have their Beta thalassemia drug candidates in the most advanced stage, i.e. Phase IIb include, Imara.
Phases
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Beta thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beta thalassemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Beta thalassemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta thalassemia drugs.

Beta thalassemia Report Insights
Beta thalassemia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Beta thalassemia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Beta thalassemia drugs?
How many Beta thalassemia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta thalassemia?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta thalassemia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Beta thalassemia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
CRISPR Therapeutics
Imara
Silence Therapeutics
Acceleron Pharma
Celgene Corporation
Kiadis Pharma
Fulcrum Therapeutics
Aruvant Sciences
Editas Medicine
EdiGene
EpiDestiny
Novo Nordisk

Key Products
CTX001
IMR-687
SLN-124
Sotatercept
ATIR-101
FTX-6058
ARU-1801
EDIT-301
ET 01
EPI 01

Introduction
Executive Summary
Beta thalassemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Beta thalassemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Beta thalassemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Beta thalassemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMR-687: Imara
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
CTX001: CRISPR Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EPI 01: EpiDestiny/Novo Nordisk
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Beta thalassemia Key Companies
Beta thalassemia Key Products
Beta thalassemia- Unmet Needs
Beta thalassemia- Market Drivers and Barriers
Beta thalassemia- Future Perspectives and Conclusion
Beta thalassemia Analyst Views
Beta thalassemia Key Companies
Appendix

Table 1 Total Products for Beta thalassemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Beta thalassemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products